Pomerantz LLP has filed a class action lawsuit against Embecta Corp. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Embecta securities during the class period have until August 17, 2026, to seek appointment as lead plaintiff. The lawsuit follows Embecta's May 5, 2026, announcement of second quarter 2026 financial results, which revealed a revenue decline of over 14% and lowered guidance for the 2026 fiscal year, causing the stock price to drop nearly 58%. Embecta attributed the lowered estimates partly to weakness in its pen needle sales.
Embecta CorpClass action lawsuit and 58% stock drop after revenue decline and lowered guidance.